Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

66th Annual Scientific Sessions of the American College of Cardiology

17 March 2017
Washington DC, USA

PlayThe Word from ACC 2017 – Implications for Practice

The Word from ACC 2017 – Implications for Practice

The highlight of ACC 2017 was the FOURIER trial, representing the culmination of the PCSK9 revolution. Here PCSK9 Forum Co-Editor Professor John Chapman and experts from the PCSK9 Forum Editorial Board discuss implications from FOURIER for clinical practice.

read more »
PlayThe Word from ACC 2017  – Key Results

The Word from ACC 2017 – Key Results

The highlight of ACC 2017 was the FOURIER trial, representing the culmination of the PCSK9 revolution. Here PCSK9 Forum Co-Editor Professor John Chapman and experts from the PCSK9 Forum Editorial Board dissect the key results and messages from FOURIER.

read more »
PlayAccess to PCSK9 inhibitor treatment: NLA survey provides important pointers

Access to PCSK9 inhibitor treatment: NLA survey provides important pointers

Professor Dean G. Karalis (Director of Preventive Cardiology, Pennsylvania Hospital, USA) discusses the issues and how to counter these. FOURIER and SPIRE-2 have clearly shown the benefits of lowering LDL cholesterol beyond current targets in very high risk patients. However, from a routine practice view,…

read more »
PlayFOURIER in the Hot Seat: What are the Implications for practice and access?

FOURIER in the Hot Seat: What are the Implications for practice and access?

FOURIER was a landmark trial for PCSK9 inhibition, showing significant reduction in cardiovascular events with evolocumab in very high risk patients on maximally tolerated lipid lowering therapy. The results from FOURIER, together with those from SPIRE-2 in patients at higher baseline LDL cholesterol levels, clearly…

read more »
PlayDr Brian Ference sets the record straight on questions about benefit in FOURIER

Dr Brian Ference sets the record straight on questions about benefit in FOURIER

In discussions at ACC.2017, some have suggested that the results of FOURIER were less than anticipated from the meta-analysis of statin trials by the Cholesterol Treatment Trialists’ Collaboration (CTTC) (1). PCSK9 Forum Editor Dr Brian Ference (Division of Cardiovascular Medicine, Wayne State University School of…

read more »
PlayEvents are the driver in PCSK9 cardiovascular outcomes trials

Events are the driver in PCSK9 cardiovascular outcomes trials

A recurrent question at ACC.2017 was why FOURIER had a short duration of follow-up, given the average duration of the statin trials was typically in the region of 4-5 years. This debate has been fanned by colourful but misinformed reports in the investment media (1).’…

read more »
PlayProf Robert Rosenson: REGARDS study adds to EBBINGHAUS reassures on lack of effect on neurocognition at low LDL-C

Prof Robert Rosenson: REGARDS study adds to EBBINGHAUS reassures on lack of effect on neurocognition at low LDL-C

In a new report today, Professor Robert Rosenson (Mount Sinai Icahn School of Medicine, Mount Sinai Hospita, New York, USA) discusses results from the REGARDS study. This study investigated whether there was any link between PCSK9 genetic variants associated with low LDL cholesterol and cognitive…

read more »
EBBINGHAUS counters claim of neurocognitive effects with PCSK9 inhibition

EBBINGHAUS counters claim of neurocognitive effects with PCSK9 inhibition

Ebbinghaus was a pioneer of memory research. One of his key contributions was the forgetting curve, which describes the exponential loss of learned information. It is therefore fitting that a trial bearing his name has shown that very low LDL cholesterol levels on PCSK9 monoclonal…

read more »
PlayProf Kausik Ray: Inclisiran, new kid on the block, looks good in ORION

Prof Kausik Ray: Inclisiran, new kid on the block, looks good in ORION

Watch out PCSK9 monoclonal antibodies: inclisiran (formerly known as PCSK9si and ALN-PCSsc) has made its mark at ACC.2017. Results of the phase 2 ORION-1 trial in patients with elevated LDL cholesterol despite maximally tolerated statin therapy, showed that 2 single injections of inclisiran 300 mg…

read more »